4//SEC Filing
TAKANASHI KEN 4
Accession 0001567619-20-020722
CIK 0001692830other
Filed
Dec 6, 7:00 PM ET
Accepted
Dec 7, 6:05 PM ET
Size
6.9 KB
Accession
0001567619-20-020722
Insider Transaction Report
Form 4
TAKANASHI KEN
Director10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-12-03+20,000→ 20,000 totalExercise: $4.60Exp: 2030-12-03→ Common Stock (20,000 underlying)
Holdings
- 1,561,719(indirect: See footnote)
Common Stock, $0.0001 par value
Footnotes (2)
- [F1]Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
- [F2]The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting.
Documents
Issuer
Satsuma Pharmaceuticals, Inc.
CIK 0001692830
Entity typeother
Related Parties
1- filerCIK 0001657768
Filing Metadata
- Form type
- 4
- Filed
- Dec 6, 7:00 PM ET
- Accepted
- Dec 7, 6:05 PM ET
- Size
- 6.9 KB